Renaissance Technologies’s Aerie Pharmaceuticals AERI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-795,473
| Closed | -$12M | – | 4558 |
|
|
2022
Q3 | $12M | Buy |
795,473
+205,163
| +35% | +$2.38M | 0.02% | 933 |
|
|
2022
Q2 | $4.43M | Buy |
590,310
+92,100
| +18% | +$649K | 0.01% | 1658 |
|
|
2022
Q1 | $4.53M | Buy |
498,210
+113,900
| +30% | +$878K | 0.01% | 1668 |
|
|
2021
Q4 | $2.7M | Buy |
384,310
+62,600
| +19% | +$655K | ﹤0.01% | 1920 |
|
|
2021
Q3 | $3.67M | Sell |
321,710
-45,663
| -12% | -$668K | ﹤0.01% | 1653 |
|
|
2021
Q2 | $5.88M | Buy |
367,373
+139,863
| +61% | +$2.4M | 0.01% | 1528 |
|
|
2021
Q1 | $4.07M | Sell |
227,510
-59,000
| -21% | -$1.02M | 0.01% | 1784 |
|
|
2020
Q4 | $3.87M | Sell |
286,510
-32,590
| -10% | -$394K | ﹤0.01% | 1745 |
|
|
2020
Q3 | $3.76M | Buy |
319,100
+33,100
| +12% | +$403K | ﹤0.01% | 1746 |
|
|
2020
Q2 | $4.22M | Buy |
+286,000
| New | +$4.23M | ﹤0.01% | 1746 |
|
|
2020
Q1 | – | Sell |
-140,600
| Closed | -$3.4M | – | 3929 |
|
|
2019
Q4 | $3.4M | Buy |
140,600
+55,600
| +65% | +$1.15M | ﹤0.01% | 2072 |
|
|
2019
Q3 | $1.63M | Buy |
+85,000
| New | +$1.95M | ﹤0.01% | 2383 |
|
|
2015
Q2 | – | Sell |
-101,400
| Closed | -$3.18M | – | 3440 |
|
|
2015
Q1 | $3.18M | Buy |
+101,400
| New | +$2.94M | 0.01% | 1659 |
|
Renaissance Technologies's AERI Position: Q4 2022 in Review
Renaissance Technologies sold out of Aerie Pharmaceuticals (AERI) in Q4 2022, closing a stake of 795,473 shares — an estimated $12M sold.
Renaissance Technologies first reported a position in AERI in Q1 2015 and held it in 13 quarters. The position peaked at $12M in Q3 2022. 0 funds tracked by Wall St. Rank hold AERI as of Q4 2022.
- Renaissance Technologies reported no remaining Aerie Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
- Renaissance Technologies sold 795,473 Aerie Pharmaceuticals shares in Q4 2022, an estimated $12M.
- Renaissance Technologies first reported a position in Aerie Pharmaceuticals in Q1 2015 and held it in 13 quarters.
- Renaissance Technologies's Aerie Pharmaceuticals position peaked at $12M in Q3 2022.
- 0 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2022.
Based on Renaissance Technologies's 13F filing for Q4 2022, filed 13 Feb 2023.